Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania
NCT03640403 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1555
Last updated 2024-11-20
Summary
Background:
In high-transmission settings, up to 70% of school-aged children harbour malaria parasites which is mostly asymptomatic, thus, from an epidemiological point of view, they contribute significantly as reservoir to onward malaria transmission to others. In endemic areas, malaria accounts for around 50% of the mortality, 13-50% of all school absenteeism, and causes anaemia in approximately 85 million school-aged children of sub Saharan Africa that also impairs the cognitive development of children. Intermittent preventive treatment (IPT) of pregnant women as well as seasonal malaria chemoprevention in children under the age of five have been implemented in several sub-Saharan countries and have proven to be very effective. However, none of these IPT strategies is targeting school children. A clinical trial is being conducted to expand the IPT by testing effectiveness and safety of two antimalarial drugs Dihydroartemisinin-piperaquine (DP) and Artesunate-amodiaquine (ASAQ) in preventing malaria related morbidity in school aged children (IPTsc) living in high endemic areas.
Methods:
A randomized, open label, controlled trial will enrol 1602 school children aged 5-15 years, who will receive either DP or ASAQ or control (no drug ), using a "balanced block design" with the "standard of care" arm as reference. The interventional treatments are given every 4 months 3 rounds for the first year. A second non-interventional year will assess possible rebound effects. All study-arms receive bed nets, early diagnosis and care for malaria, and praziquantel and albendazole as mass treatment for helminthiasis. The primary endpoint are change from baseline in mean haemoglobin concentration at months 12 and 20 of follow-up and clinical malaria incidence from month 0 till months 12 and 20 of follow up. Adverse events will be monitored throughout the study. Mixed design methods will be used to assess the acceptability, cost-effectiveness and feasibility of this IPTsc as part of a more comprehensive school children health package.
Discussion:
The national school health programme (NSHP), Tanzania, combines schistosomiasis and soil transmitted helminthes (STH) control package under national schistosomiasis and STH control programme (NSSCP). Malaria intervention using IPTsc strategy may be integrated in NSHP with the same platform as NSSCP, however, there is limited systematic evidence to assess the operational feasibility of this approach. School aged children are a reachable target population in any endemic malaria setting. The suggested strategy will provide effective protection against malaria, hasten either the elimination process and/or diminish the reservoir and burden.
Conditions
- Malaria,Falciparum
- Anemia
Interventions
- DRUG
-
Dihydroartemisinin-piperaquine
Dihydroartemisinin-piperaquine (DP). One of the Artemisinin combination therapy(ACTs), indicated for treatment of uncomplicated malaria. It will to be given every 4 months 3 rounds for a year.
- DRUG
-
Artesunate-amodiaquine
Artesunate-amodiaquine (ASAQ). One of the Artemisinin combination therapy(ACTs), indicated for treatment of uncomplicated malaria. It will to be given every 4 months 3 rounds for a year.
Sponsors & Collaborators
-
Universiteit Antwerpen
collaborator OTHER -
National Institute for Medical Research, Tanzania
lead OTHER_GOV
Principal Investigators
-
John PA Lusingu, MD, PhD · National Institute for Medical Research, Tanzania
-
Jean-pierre Van geertruyden, MD, PhD · Global health institute, University of Antwerp, Belgium.
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 5 Years
- Max Age
- 15 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2019-03-26
- Primary Completion
- 2020-12-31
- Completion
- 2021-12-31
Countries
- Tanzania
Study Locations
More Related Trials
-
Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar
NCT03764527 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in Cambodia
NCT02612545 ·Status: COMPLETED ·Phase: PHASE1
-
Assessing the Efficacy of Artemisinin Combination Therapies for Treatment of Uncomplicated Malaria Infection in Children
NCT01082705 ·Status: COMPLETED ·Phase: PHASE3
-
Dihydroartemisinin-piperaquine for Seasonal Malaria Chemoprophylaxis in Tanzania
NCT05874869 ·Status: COMPLETED ·Phase: NA
-
Efficacy Study of Amodiaquine-Artesunate and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria
NCT01567423 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Artesunate + Amodiaquine Four Years After Its Introduction in Zanzibar
NCT00465257 ·Status: SUSPENDED ·Phase: PHASE4
-
In Vivo Efficacy of Artemether-Lumefantrine, Amodiaquine-Artesunate, Dihydroartemisinin-Piperaquine, and Pironaridine-Artesunate in Mozambique
NCT05343312 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of a Single Low-dose Primaquine for the Clearance of Gametocytes
NCT02090036 ·Status: COMPLETED ·Phase: PHASE4
-
A Randomized Trial of Coartemether and Artekin for the Treatment of Uncomplicated Malaria in Papua, Indonesia.
NCT00157833 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Uncomplicated Malaria in South Kivu, DR Congo
NCT02741024 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Artemether-Lumefantrine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Under 12 Years at Four Sentinel Sites in Mozambique
NCT06970600 ·Status: COMPLETED ·Phase: NA
-
Malaria Therapeutic Efficacy Study, Rwanda
NCT04767217 ·Status: COMPLETED ·Phase: PHASE4
-
Chloroquine and Coartem for Treatment of Symptomatic Children With Plasmodium Falciparum in Guinea Bissau
NCT00426439 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Artemisinin-based Combination Treatments in the Democratic Republic of the Congo
NCT02940756 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Artesunate + Amodiaquine With SLD of Primaquine for Treatment of Falciparum Malaria in Zanzibar
NCT03773536 ·Status: COMPLETED ·Phase: PHASE4
-
Treatment of Uncomplicated Childhood Malaria in Tanzania by Artemether+Lumefantrine - Efficacy and Genotyping
NCT00336375 ·Status: COMPLETED ·Phase: PHASE4
-
A Trial of Four Drug Regimens for the Prevention of Malaria in Senegalese Children
NCT00132548 ·Status: COMPLETED ·Phase: PHASE3
-
Malaria in Early Life Study
NCT02001428 ·Status: COMPLETED ·Phase: NA
-
Reducing the Risk of P. Vivax After Falciparum Infections in Co-endemic Areas
NCT03916003 ·Status: COMPLETED ·Phase: PHASE4
-
Artemisinin-Based Antimalarial Combinations and Clinical Response in Cameroon
NCT01845701 ·Status: COMPLETED ·Phase: PHASE3
-
Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa
NCT02974348 ·Status: COMPLETED ·Phase: PHASE3
-
Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial
NCT05764746 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Safety and Efficacy of Methylene Blue Combined With Artesunate or Amodiaquine for Malaria Treatment in Children of Burkina Faso: a Pilot Study
NCT00354380 ·Status: COMPLETED ·Phase: PHASE2
-
Surveillance and Treatment With Dihydroartemisinin-piperaquine Plus Primaquine
NCT01878357 ·Status: COMPLETED ·Phase: PHASE4
-
ACT for the Home Management in Malagasy Children
NCT00612547 ·Status: COMPLETED